Patients with Hodgkin lymphoma post-transplant lymphoproliferative disorder (HL-PTLD) have inferior survival vs patients with Hodgkin lymphoma and listed in the Surveillance, Epidemiology, and End Results (HL-SEER) database. This according to a study of 192 patients with HL-PTLD and 13,847 patients with HL-SEER. Researchers found:

• Compared with HL-SEER, patients with HL-PTLD were older (age 52 vs 36 years), more likely male (73% vs 54%), White (81% vs 70%), and had extranodal disease (42% vs 3%).

• 5-year OS for patients with HL-PTLD was 57% vs 80% for HL-SEER.

• For patients with HL-PTLD, use of any chemotherapy was associated with decreased hazard of death (HR=0.36).

• Patients who received no chemotherapy (aHR=2.94) or non-traditional HL regimens (aHR=2.01) had increased hazard of death vs HL-specific chemotherapy regimens.

• In multivariable analysis, advanced age (aHR=1.26/decade) and elevated creatinine (aHR=1.64/0.1mg/dL increase) were associated with inferior overall survival (OS).

• A prognostic score based on the number of adverse factors present (0, 1, 2) was associated with 10-year OS rates of 79%, 53%, and 11%, respectively.

Citation: Rosenberg AS, Klein AK, Ruthazer R, Evens AM. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. [Published online ahead of print March 1, 2016]. Am J Hematol. doi:10.1002/ajh.24346.